Daiichi Sankyo Company, Limited (4568.T)

5.531,00 0,00 (0,00%) Alla chiusura: 03:15PM JST

Daiichi Sankyo Company, Limited

3-5-1, Nihonbashi-honcho
Chuo-ku
Tokyo 103-8426
Japan
81 3 6225 1111
https://www.daiichisankyo.com

Settore/i: Healthcare
Settore: Drug Manufacturers - General
Impiegati a tempo pieno: 

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Sunao Manabe D.V.M., Ph.D.	Group CEO & Executive Chairperson	280M	N/D	1954
Mr. Hiroyuki Okuzawa	President, COO & Representative Director	110M	N/D	1962
Dr. Shoji Hirashima	Senior Managing Executive Officer, Head of Japan Business Unit & Representative Director	119M	N/D	1961
Mr. Koji Ogawa	Managing Executive Officer, Head of Global Corporate Planning & Management and CFO	N/D	N/D	N/D
Chiyu	General Manager of Finance & Accounting Department	N/D	N/D	N/D
Hiroto Kashiwase	Managing Executive Officer & Head of Technology Division	N/D	N/D	N/D
Naoto Tsukaguchi	Gen. Counsel, Corp. Officer, Head of Global Legal & IP and VP of Leg. Aff. Dept.	N/D	N/D	N/D
Matt Allegrucci	Head of Global Compliance & Risk Management and Chief Compliance Officer	N/D	N/D	N/D
Kentaro Asakura	Vice President of Corporate Communications Department	N/D	N/D	N/D
Ms. Marielle Cohard-Radice M.D.	Global Head of Development	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in JPY.

Descrizione

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.

Governance aziendale

L'ISS Governance QualityScore di Daiichi Sankyo Company, Limited al 1 maggio 2024 è 1. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 1; diritti degli azionisti: 2; retribuzione: 1.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.